Dr Tedros Adhanom Ghebreyesus, WHO Director-General, has appointed Dr. Ayoade Alakija as WHO Special Envoy for the Access to COVID-19 Tools Accelerator (ACT-Accelerator).
In her capacity as Special Envoy, Dr Alakija will help lead the collective advocacy for the ACT-Accelerator, mobilizing support and resources so it can deliver against its new Strategic Plan and Budget that was launched on 28 October 2021, and ensuring that the response is characterised by accountability, inclusion, and solidarity.
Dr Alakija will also support the leaders of the ACT-Accelerator’s three product pillars (vaccines, tests, treatments) and cross cutting ‘connector’; consult widely on the work of the ACT-Accelerator; advise the Director-General, ACT-Accelerator principals and stakeholders on emerging issues; and represent the ACT-Accelerator in key national and international fora.
Dr Alakija joins the ACT-Accelerator at a critical moment in the global COVID-19 response, where the emergence of new variants of concern and missed global coverage targets leave large swathes of the world’s population unvaccinated, untested and untreated.
507
公平获得疫苗、检测、治疗和个人防护装备的必要性对于结束大流行的急性期仍然至关重要。
The need for equitable access to vaccines, testing, treatments and personal protective equipment (PPE) remains vitally important to bringing an end to the acute phase of the pandemic.
The ACT-Accelerator partnership, a coalition of leading public health organizations, is the only global initiative offering an integrated, end-to-end solution to expedite the end of the pandemic through the accelerated development and equitable distribution of vaccines, tests and treatments.
509
Alakija博士是一名医学博士，拥有伦敦卫生和热带医学院公共卫生和流行病学硕士学位。
Dr Alakija is a medical doctor with a Masters degree from The London School of Hygiene and Tropical Medicine in Public Health and Epidemiology.
510
她是一名全球卫生领导人和活动家，通过外交手段使全球北方和南方团结起来，协调应对大流行疫情。
She is a global health leader and activist who has deployed diplomacy to bring together the global north and south together in coordinated responses to the pandemic.